A prospective open label randomised phase-I seamlessly followed by phase-II study to assess the safety, reactogenicity and immunogenicity of biological E's novel Covid-19 vaccine containing receptor binding domain of SARS-CoV-2 for protection against - Thuluva, S
2020. Accessed January 24, 2022 at: